Janssen seeks EMA nod for Imbruvica, rituximab combo in previously untreated CLL
Imbruvica is already approved in Europe for chronic lymphocytic leukaemia as a monotherapy or in combination with obinutuzumab in patients who were previously untreated for their condition. The